Home / Intelligence / White Papers / Measuring the Impact of Field Medical Affairs
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in HCP perception, HCP advocacy or closing critical care gaps that impact overall patient outcomes.
When developing Key Medical Objectives (KMOs) and impact measurement models for Field Medical Affairs, several factors must be considered: the organization’s size, structure, specific roles, therapeutic area, asset lifecycle stage and strategic priorities. A flexible, customized model is critical to adapt to the evolving role of Field Medical Affairs, allowing teams to prioritize different measures based on their unique needs and situations. Additionally, HCP perceptions and patient outcomes should be prioritized over quantitative activity metrics with the goal of enhancing clinical practice and standards of care. As an industry, we must acknowledge that implementing this paradigm shift requires time and thoughtful investment.
Trinity Life Sciences advocates for careful, rigorous planning and tailoring the right Field Medical Affairs impact measures to meet our clients at their point of need. Trinity offers extensive expertise and a wide range of capabilities to support clients through this transformation, helping them build a “Best in Class” Field Medical Affairs program.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Read More
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More
Blog
Key Takeaways and Learnings from ISPOR Europe 2023
Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both academics and the life sciences industry, including manufacturers, regulatory leaders and health economists, to […]
Read More